“Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s2. doi:10.25251/skin.5.supp.2.